Study of AT-752 in Patients With Dengue Infection

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Atea Pharmaceuticals, Inc.

Criteria

Key Inclusion Criteria:

• 18-55 years of age at time of screening

• Fever ≥38°C (or feeling feverish) with onset during the previous 48 hours

• Live/work in or recent travel to dengue endemic area

• Positive test confirming DENV on a NS1 antigen test or reverse transcription-polymerase chain reaction (RT-PCR) assay

• Negative rapid diagnostic test result for SARS-CoV-2 and Influenza A and B

Key Exclusion Criteria:

• Pregnant, plans to become pregnant within 90 days of screening, or breast feeding.

• Has previously received any investigational or approved vaccine for dengue

• Previous history of HIV, chronic hepatitis B infection, or current hepatitis C infection (from medical history)

• Use of any antiviral drug within 30 days or within 5 half-lives of the active drug or metabolite (for long-acting antivirals)

• Current use of anticoagulant or antiplatelet drugs or documented medical history of bleeding disorders

• Current use of medications for treatment of inflammatory bowel disease or documented medical history of chronic gastrointestinal disease including inflammatory bowel disease

• Immunocompromised due to use of immunosuppressive drugs including systemic corticosteroids (inhaled or topical corticosteroids are allowed) or any current disease or condition

• Evidence of severe dengue disease

• Confirmed or suspected SARS-CoV-2 infection or contact with patients with confirmed SARS-CoV2 infection within 7 days prior to screening

• Other clinically significant medical conditions or laboratory abnormalities, as described in the protocol.